Nextbio Research Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
- Paid Up Capital ₹ 2.79 Cr
- Company Age 8 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth %
- Profit Growth 93.39%
- Ebitda 94.54%
- Net Worth -0.44%
- Total Assets -6.26%
About Nextbio Research
Nextbio Research Private Limited (NRPL) is a Private Limited Indian Non-Government Company incorporated in India on 02 August 2016 (Eight years and six months 3 days old ). Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 2.79 Cr, as per Ministry of Corporate Affairs (MCA) records.
Umesh Bisile and Nagendra Nagasundar serve as directors at the Company.
Company Details
-
Location
Bangaluru, Karnataka, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U73100KA2016PTC095455
-
Company No.
095455
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
02 Aug 2016
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Nextbio Research?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Umesh Bisile
|
Director | 02-Aug-2016 | Current |
|
Nagendra Nagasundar
|
Director | 02-May-2017 | Current |
Financial Performance of Nextbio Research.
Nextbio Research Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 93.39% increase in profit. The company's net worth dipped by a decrease of 0.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nextbio Research?
In 2022, Nextbio Research had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Invitro Research Solutions Private LimitedUmesh Bisile is a mutual person
-
Biostec Data Safety Services Private LimitedUmesh Bisile is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nextbio Research?
Nextbio Research has a workforce of 2 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nextbio Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nextbio Research's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
